Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
329.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 14.00 (4.348%)
Market Cap: £41.75m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

15 Jul 2016 07:00

RNS Number : 2623E
BrainJuicer Group PLC
15 July 2016
 

 

 

 

Press Release

15 July 2016

 

 

BrainJuicer Group PLC (AIM: BJU)

("BrainJuicer", or "the Company")

 

Six month Trading Update

 

BrainJuicer, the innovative international market research agency, today releases the following six month ("H1") trading update. The Company will announce its interim results for the six months to 30 June 2016 on 16 September 2016.

 

Top line growth during H1 was generally encouraging. Revenue increased by 13%, and by 9% in constant currencies, and gross profit (our main top-line performance indicator) grew by 15%, and 11% in constant currencies. Our largest market, the US, performed strongly, with gross profit rising by some 27%; gross profit in Continental Europe and Brazil also grew well, increasing by 30% and 22% respectively. Gross profit in our second largest market, the UK, declined by 2%, and in our China and Singapore region it also declined slightly by 5%.

 

Our Ad Testing and Brand Tracking services continued to grow strongly, with gross profit up 59% year on year. Much of this business is Ongoing in nature (as opposed to Ad Hoc), and builds on the "Fame, Feeling & Fluency" approach to brand building that we introduced last year.

 

After factoring in our new creative agency, System1, which was launched during H1 and, as anticipated, incurred costs of some £0.3m, BrainJuicer's operating profit increased by some 41% to around £1.7m. After adjusting for exceptional items (share based payments and also the one-off costs in H1 2015 relating to due diligence work and our Head Office move) normalized H1 pre-tax profit will be similar to the £1.7m reported in 2015.

 

BrainJuicer's financial position remains strong. At the end of June the Company had a cash balance of £5.2m (December 2015: £6.4m), after returning £2.2m to shareholders during H1 by way of dividends and share buy-backs.

The Company generates the majority of its annual profit in the second half of the year, and whilst our revenue visibility is, as ever, limited the Board believes that the Company is in a position to meet market expectations for the full year.

 

The decline in the value of sterling versus the US Dollar, the Euro and other leading currencies following the referendum on the UK's membership of the EU benefits the Company's non-UK profits reported in sterling. The results of our overseas businesses are translated into sterling using monthly average exchange rates. Beyond this, it is too early to say what the impact of the UK's exit from the EU on the market research budgets of our clients is likely to be.

 

This announcement contains inside information. The Company can be found at www.brainjuicer.com.

 

For further information, please contact:

BrainJuicer Group PLC

Tel: +44 (0)20 7043 1000

 

John Kearon, Chief Executive Officer

 

James Geddes, Chief Financial Officer

 

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

Simon Bridges / Henry Fitzgerald-O'Connor / Emma Gabriel

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUSABRNWABAAR
Date   Source Headline
7th Jan 20227:00 amRNSShare Buyback Programme
4th Jan 20222:00 pmRNSDirectorate Change
30th Nov 20214:51 pmRNSDirector Dealings
30th Nov 20217:00 amRNSINTERIM RESULTS
9th Nov 20217:00 amRNSComplaint for Trademark Infringement
29th Oct 20211:24 pmRNSGrant of Options
20th Oct 20217:00 amRNSTrading Update
13th Aug 20215:24 pmRNSAnnual General Meeting
13th Aug 20217:00 amRNSTrading Update for the Annual General Meeting
4th Aug 20216:15 pmRNSUpdate re 2021 AGM
20th Jul 20212:30 pmRNSAnnual Report and Notice of AGM
14th Jul 20217:00 amRNSFinal Results
23rd Jun 202112:30 pmRNSNotice of Results
21st May 20217:00 amRNSExercise of Options and Total Voting Rights
17th May 202112:12 pmRNSDirector/PDMR Shareholding
28th Apr 20211:08 pmRNSDirector/PDMR Shareholding
23rd Apr 202111:16 amRNSCorrection re Directors Dealings
23rd Apr 20219:40 amRNSExercise of Options, Directors Dealings and TVR
21st Apr 20217:00 amRNSTrading Update
30th Mar 20217:00 amRNSChange in Executive Job Titles
15th Feb 202112:42 pmRNSBoard Changes
12th Feb 202111:00 amRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSDirector/PDMR Shareholding
2nd Dec 20204:30 pmRNSGrant of Options
27th Nov 20207:00 amRNSDirector/PDMR Shareholding
17th Nov 20206:27 pmRNSDirector/PDMR Shareholding
17th Nov 20207:00 amRNSInterim Results
14th Oct 20207:00 amRNSTrading Update
12th Oct 20201:40 pmRNSHolding(s) in Company
7th Oct 20202:33 pmRNSHolding(s) in Company
24th Sep 20204:08 pmRNSHolding(s) in Company
4th Aug 20209:39 amRNSDirector/PDMR Shareholding - Replacement
3rd Aug 20205:33 pmRNSDirector/PDMR Shareholding
31st Jul 20206:34 pmRNSResult of AGM
6th Jul 20204:33 pmRNSAnnual Report and Notice of AGM
3rd Jul 202012:22 pmRNSDirector/PDMR Shareholding
2nd Jul 202010:04 amRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSFinancial results to 31 March 2020
26th Jun 20202:00 pmRNSExercise of Options and Total Voting Rights
26th Jun 20207:00 amRNSDirectorate Change
26th Jun 20207:00 amRNSDirectorate Change
27th Apr 20207:00 amRNSTrading Update
3rd Apr 20207:00 amRNSChief Financial Officer Resignation
24th Mar 20204:40 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTrading Update and Planned Share Buyback
23rd Dec 20193:30 pmRNSExercise of Options and Total Voting Rights
7th Nov 20199:29 amRNSDividend Declaration
7th Nov 20197:00 amRNSInterim Results
14th Oct 20197:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.